Par Drugs and Chemicals Ltd
NSE:PAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Par Drugs and Chemicals Ltd
Revenue
Par Drugs and Chemicals Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Par Drugs and Chemicals Ltd
NSE:PAR
|
Revenue
₹1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Revenue
₹346.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Revenue
₹283.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Revenue
₹568.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Revenue
₹261.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Revenue
₹127.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
Par Drugs and Chemicals Ltd
Glance View
Par Drugs & Chemicals Ltd. engages in the development and manufacture of Active Pharma Ingredients (API) for the domestic market as well as for exports to international markets. The company is headquartered in Bhavnagar, Gujarat. The company went IPO on 2019-05-16. The firm also produces a range of antacid molecules. The Company’s products include magnesium hydroxide, magnesium trisilicate, magnesium carbonate, light magnesium oxide, magnesium oxide heavy, magnesium oxide USP, dried aluminum hydroxide gel, magaldrate, magnesium aluminum silicate hydrated, alma gate, hydrotalcite, aluminum hydroxide magnesium carbonate co-dried gel, aluminum-magnesium silicate BP, sodium aluminum silicate, precipitated silica, magnesium silicate, amorphous, colloidal silicon dioxide and sucralfate USP. The firm owns and operates its manufacturing facilities at Bhavnagar in Gujarat. The company has over four manufacturing blocks at Bhavnagar, which are for different products having a capacity of approximately 9,700 metric tons per annum.
See Also
What is Par Drugs and Chemicals Ltd's Revenue?
Revenue
1B
INR
Based on the financial report for Mar 31, 2025, Par Drugs and Chemicals Ltd's Revenue amounts to 1B INR.
What is Par Drugs and Chemicals Ltd's Revenue growth rate?
Revenue CAGR 5Y
13%
Over the last year, the Revenue growth was 6%. The average annual Revenue growth rates for Par Drugs and Chemicals Ltd have been 10% over the past three years , 13% over the past five years .